THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL
NCT ID: NCT06004375
Last Updated: 2023-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
20 participants
INTERVENTIONAL
2021-05-01
2023-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
-to test the effect of oral nutritional supplements containing arginine and glutamine on covid-19 patients outcome Dr. M. Djamil General Hospital Padang
Participants will given ONS containing arginine and glutamine. Researchers will compare intervention group with control group to see if ONS affected outcome of COVID-19 patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glutamine Supplementation and Short-term Mortality in Covid-19
NCT04909905
Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19
NCT04703036
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
NCT04706416
Effects of Oral Care With Glutamine on Oral Health, Oral Flora and Incidence of Pneumonia After Neurosurgery With Microbiome Analysis
NCT03867214
Trial of Oral Glutamine on Mitochondrial Function in CKD
NCT02838979
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intervention group
The intervention group was given a High-Calorie High-Protein + ONS diet containing 4.8 g arginine and 2 g glutamine, namely Neomune 2x 200 cc, purchased from Otsuka Pharmaceutical Co., Ltd
Neomune
Neomune containing 4.8 g arginine and 2 g glutamine
control group
the control was administered with a High-Calorie High-Protein diet + ONS hospital standard.
Neomune
Neomune containing 4.8 g arginine and 2 g glutamine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neomune
Neomune containing 4.8 g arginine and 2 g glutamine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age over 17 years
* The patient can take food orally
Exclusion Criteria
* Patients who cannot take food orally
* suffering from diabetes mellitus and kidney failure
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M. Djamil General Hospital
UNKNOWN
Universitas Sriwijaya
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sari Bema Ramdika
Ms
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. M. Djamil General Hospital
Padang, West Sumatera, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.